Although cancer has long been a major public health problem worldwide, conquering cancer still remains unachievable due to its complexity and diversity. With the development of high-throughput sequencing technologies, the combination of conventional clinical symptoms and new genetic events is becoming effective and has been approved for precise prediction and innovative diagnostic strategies. Epigenetic modification (e.g., DNA methylation) is an important mechanism of transcriptional control in normal or disease functions. Depending on the unique methylation profiles, an important possibility raised is that the characteristic of dys-methylation could provide a new molecular marker system for the identification of the major forms of tumors. In this study, we attempted to distinguish different tumor types. On the basis of DNA methylation data from PanCanAtlas in The Cancer Genome Atlas, we applied mRMR and MCFS methods together to identify the decision rules for distinguishing 33 different tumor types and ranked the features that characterized methylation level. This study highlights the considerable application potential of methylation features in cancer diagnosis and provides insight into novel therapeutic targets.
I. INTRODUCTION
For centuries, cancer has been a major public health problem worldwide. Numerous scientists have devoted themselves to cancer research and attained notable achievements [1] . Nevertheless, the desired goal to conquer cancer remains unachievable because of its complexity and diversity. Cancer can be characterized into different forms in accordance with tumor location, cellular origin, biological process, and genomic alteration profiles, all of which can enhance oncogenesis or affect therapeutic response. Each type of cancer has a unique spectrum of genetic aberrations, including single nucleotide variations, copy number variations, varied gene expression profiles, and different epigenetic alterations [2] .
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With the development of sequencing technologies, precise and innovative prediction and diagnostic strategies based on the combination of conventional clinical symptoms and new genetic events have become effective and been approved [3] . These strategies are expected to further contribute to cancer treatment in the next decades.
Among genetic events, epigenetic modification (e.g., DNA methylation) is an important mechanism of transcriptional control in mammals. It plays a crucial role in maintaining cellular function on the basis of the proper regulation of gene expression and stable gene silencing in normal cells. However, promoter hypermethylational silencing has been confirmed to give rise to cancer through the transcriptional inhibition of critical growth regulators, such as tumor suppressor genes [4] , [5] . Numerous pieces of evidence also point that DNA methylation has a direct role in carcinogenesis. VOLUME 8, 2020 This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see http://creativecommons.org/licenses/by/4.0/ For example, the promoter regions of retinoblastoma and von Hippel-Lindau genes are hypermethylated in unilateral retinoblastoma and renal cancer, respectively [6] , [7] . Similarly, the p16INK4a promoter is methylated in lung cancer and mammary epothelial cells [8] , and the frequency of aberrant methylation increases with disease progression [9] . This phenomenon indicates that aberrant hypermethylation events act as a primary inactivating event contributing to tumorigenesis.
Certain genes, such as cell cycle inhibitor P16INK4A, exhibit promoter hypermethylation in almost all types of cancers, whereas some others genes would display high frequencies of methylation only in very specific tumor types. For example, GSTP1 is hypermethylated in liver, breast, and kidney cancers but shows little or even no methylation in other tumor types [10] . Similarly, the hypermethylation of BRCA1 is found only in breast and ovarian carcinomas [11] , whereas the methylation of mismatch repair gene hMLH1 is restricted to three tumor types: colorectal, endometrial, and gastric tumors [12] , [13] . An important possibility raised on the basis of the unique profiles of methylation is that the characteristic of gene methylation alterations might provide a molecular marker system for the identification of the major forms of tumors, which can be considered as potentially powerful strategies for cancer diagnosis.
The Cancer Genome Atlas (TCGA) is a well-known landmark cancer genomics program that aims to catalogue and discover molecular aberrations through large-scale genome sequencing and multidimensional analyses at the DNA, RNA, protein, and epigenetic levels [14] . This project provides access to cancer genomic datasets so that researchers could apply them to improve scientific inquiry, diagnostic methods, and eventual cancer treatments. By now, over 30,000 cancer cases have been recruited, which can be classified into 33 different tumor types. The Pan-Cancer analysis project was launched by TCGA to identify molecular aberrations among distinct cancer types that otherwise would have been missed and to broaden analytical breadth by defining commonalities and differences across cancer types and organs of origin [15] .
In this study, we aimed to construct an impactful approach for distinguishing different tumor types. This approach may provide insight into novel therapeutic targets. On the basis of DNA methylation data from PanCanAtlas, we applied the minimum redundancy maximum relevance (mRMR) [16] and Monte Carlo feature selection (MCFS) [17] methods together to identify the decision rules that distinguish 33 different tumor types and ranked the features that were characteristic of methylation level. This study highlights the potential application of methylation features in cancer diagnosis.
II. MATERIALS AND METHODS

A. DATASET
The 450K methylation profiles of TCGA pan-cancers were downloaded from PanCanAtlas (https://gdc.cancer.gov/aboutdata/publications/pancanatlas). A total of 9,664 samples belonging to 33 cancer types were retrieved. The sample size of each cancer type is listed in Table 1 . The beta values of 450K methylation probes were used to represent each cancer sample. We explored the methylation landscape of different cancer types and investigated the cancer-specific epigenetic patterns.
B. FEATURE RANKING
Different feature ranking methods can yield different important features in accordance with their principles. Thus, these methods should be evaluated and analyzed together. In this study, we used max relevance (MR) score to filter the original features and remain relevant features with large MR scores. Then we applied two widely used feature selection methods respectively, mRMR [16] and MCFS [17] , to rank these relevant features. Finally, we performed incremental feature selection (IFS) [18] on the basis of the two lists of top-ranked features by applying an integrated supervised classifier and obtained the optimal features with the best classification performance in distinguishing samples from 33 cancers.
MR score. If one feature is closely relevant to the output class, then this feature should be important. In this study, we calculated the MR score for each feature, which was defined as the mutual information between class labels and the feature.
mRMR. The mRMR method [16] , [19] - [22] measures the contribution of each feature in classification according to its trade-off between the maximum relevance and the minimum redundancy, e.g. one feature has a high rank in selected feature list when it has large relevance with class label and small redundancy with other already selected features. mRMR program was retrieved from http://home.penglab.com/proj/mRMR/index.htm. The output mRMR feature list was used in the following procedures.
MCFS. MCFS is a decision tree-based feature selection method [17] , [23] - [25] . It constructs multiple decision trees, and each tree is grown on the bootstrap sample set and feature subset. First, p bootstrap sets are randomly generated by sampling with replacement, and t feature subsets are generated with a much smaller number of features randomly sampled from the original features. In total, p × t decision trees are grown on the basis of the combination of these bootstrap sets and feature subsets. On the basis of these decision trees, a relative importance (RI) score is calculated for each feature, and highly important features will be selected as (node) features in the decision trees with high frequency. The RI score of each feature is calculated in accordance with the number of splits involving this feature for all p × t trees and weighted on the basis of the classification accuracy of individual decision trees. In this study, one MCFS implementation is adopted and downloaded from http://www.ipipan.eu/staff/m.draminski/mcfs.html. After the RI score of each feature was computed, all features were ranked in the decreasing order of their RI scores.
IFS. Given the above feature ranking by mRMR and MCFS, we further selected the optimum features with the best classification performance instead of using an arbitrary or experience-based score cutoff. Thus, we performed IFS with an integrated supervised classifier (i.e., random forest (RF)) to select the optimum features. A series of feature subsets are constructed on the basis of the top 2000 ranked features. Feature subset 1 contains the top one feature, then feature subset 2 contains the top two features, and so on. For each feature subset, a classifier is trained and evaluated on the samples consisting of the features from this feature subset using 10-fold cross-validation. In the end, an optimum feature subset with the best performance is selected.
C. RF
RF is a widely used supervised ensemble classifier consisting of multiple decision trees [20] , [26] - [29] . In RF, each decision tree is grown on one bootstrap set and a feature subset randomly selected from the original features. During the growth of individual trees, RF uses out-of-bag error to estimate the generalization ability on the out-of-bag samples, which are the remaining samples not in the bootstrap set but in the original training set. After training multiple decision trees, given a new instance, RF predicts its class label in accordance with the maximum predicted probability of these prior-trained multiple decision trees.
D. RIPPER
Compared with RF, Repeated Incremental Pruning to Produce Error Reduction (RIPPER) [30] can provide a more understandable prediction on the basis of classification rules, thus facilitating the discovery of additional details about the contribution of gene methylation to different cancers.
RIPPER is a greedy rule-learning method that is based on sequential covering. It learns some IF-THEN rules. One rule is that if the methylation values of several genes are greater or smaller than some values in one sample, then a certain prediction about the cancer types of this sample can be made. For binary classification, RIPPER first learns a rule from the training set, and all samples covered by this rule are removed. Then, the next rule is learned on the remaining samples. This learning process is repeated until all samples in the training set are classified on the basis of the produced rules. RIPPER takes a one-vs-all strategy for multiclass classification. It first orders the classes in accordance with the number of samples in the training set. Then, it learns a rule for the least common class, where the positive samples are from this class and the negative samples are from other classes. Next, the samples covered by this rule are removed, and a second rule is learned from the remaining samples for the second least common class, and so on. The last class is a default rule, which predicts a new instance to this class if the above learned rules cannot be satisfied. In this study, we used JRip implemented in MCFS package for RIPPER analysis.
E. PERFORMANCE MEASUREMENT
In this study, we applied RF and RIPPER as the multiclassification classifiers to classify samples from the 33 cancers in TCGA. Performance was evaluated by measurements of individual accuracy, overall accuracy and Matthews correlation coefficient (MCC) [20] , [31] - [34] using 10-fold crossvalidation [35] , [36] .
The individual accuracy is defined for each class (cancer type), which is the proportion of correctly predicted samples in one class among all samples in such class. Clearly, these accuracies cannot fully assess the performance of classifiers. The overall accuracy is further employed, which is defined as the proportion of correctly predicted samples among all samples. Its calculation formula is
where n is the number of correctly predicted samples and N stands for the total number of samples. As listed in Table 1 , sizes of 33 cancer types are of great differences. The biggest cancer type contains about 87 times samples as many as those in the smallest cancer type. In this case, overall accuracy is not a good measurement. The MCC in multi-class was employed in this study because it is deemed as a balanced measurement VOLUME 8, 2020 even if the class sizes greatly vary. It is defined as
where X and Y stand for two binary matrices. X represents the predicted class of each sample and Y indicates the true class of each sample.
III. RESULTS
In this study, we analyzed the methylation profiles of samples in 33 cancer types. Entire procedures are illustrated in Fig. 1 .
A. RESULTS OF FEATURE RANKING BY MRMR AND MCFS
We first calculated MR scores for all input features (e.g., methylation sites). We only retained features with MR scores greater than 0.3, i.e., 53,435 important futures of methylation as given in Tables S1 and S2. We further ranked these features by using mRMR and MCFS. Obtained feature lists are given in Tables S1 and S2, respectively.
B. RESULTS OF THE CLASSIFICATION PERFORMANCE OF RF
Given that training on the above ranked feature lists is time consuming, we first selected the top 2,000 features and generated 2,000 ordered feature subsets on the basis of the feature list yielded by mRMR method. Then, we ran IFS with an integrated RF for classifying samples from 33 cancers. Given one feature subset, RF was trained and evaluated on the samples consisting of features from this feature subset with 10-fold cross-validation. The performance measurements corresponding to different numbers of features are given in Table S3 . For easy observation, a curve was plotted in Fig. 2A with MCC as the Y-axis and number of used features as X-axis. It can be observed that when the top 1768 features were used, RF yielded the best MCC value of 0.955 ( Table 2) . The corresponding overall accuracy was 0.957 ( Table 2) . For 33 individual accuracies, seven cancer types received perfect classification and the accuracies on 24 cancer types were larger than 0.950. The detailed performance of such RF classifier on each cancer type is shown in Fig. 3A . Furthermore, by carefully checking the performance measurements listed in Table S3 , the MCC and overall accuracy can reach 0.940 and 0.943 ( cross-validation. The overall accuracy of such RF classifier was 0.973 ( Table 2 ). Fig. 3B shows the individual accuracies on 33 cancer types. This RF classifier gave perfection classification on ten cancer types and 29 cancer types received the accuracies higher than 0.950. Like to the mRMR results, we also found that RF yielded a high MCC value of 0.950 and overall accuracy of 0.952 ( Table 2 ) when using the top 211 features (called optimum set 2). The performance of this classifier on 33 cancer types is illustrated in Fig. 3B . They were almost same as those of RF with top 1805 features.
From the above results, we can see that RF yielded a similar performance when using the top features ranked by mRMR or MCFS, but the number of overlapping features between optimum set 1 and 2 is small in this work. Thus, in the discussion below, we separately analyzed the methylation features in optimum sets 1 and 2.
C. RESULTS OF THE CLASSIFICATION PERFORMANCE OF RIPPER
RIPPER is much more time-consuming than RF. Thus, we ran the IFS with RIPPER on the top 250 features ranked by mRMR and MCFS (i.e., covering the features in optimum sets 1 and 2). First, we evaluated RIPPER on the top features ranked by mRMR. The performance measurements corresponding to different number of features are given in Table S5 . For easy observation, a curve was plotted in Fig. 4A , where Y-axis represents MCC and X-axis stands for the number of used features. The best MCC value of 0.828 ( Table 2 ) when using the top 221 features. The overall accuracy yielded by such classifier was 0.835 ( Table 2) . 33 individual accuracies are shown in Fig. 5A , where nine accuracies exceeded 0.900. It can be seen that this RIPPER classifier was much inferior to above-mentioned RF classifiers. However, it can provide more insights. Furthermore, RIPPER can provide an MCC value of 0.782 ( Table 2 ) when using the top 48 features. The overall accuracy of this classifier was 0.791 ( Table 2) . They were all about 4% lower than those of RIPPER with top 221 features. The individual accuracies are also shown in Fig. 5A . On most cancer types, this classifier gave lower performance than RIPPER with top 221 features. However, it can execute with less time because it used much less features. Thus, we believed that this classifier was a more proper choice. Similarly, we also evaluated RIPPER on the features ranked by MCFS. The performance measurements corresponding to different number of features are given in Table S6 . As shown in Fig. 4B and Table 2 , RIPPER yielded the best MCC value of 0.831 when the top 249 features were used. The overall accuracy was 0.838. Detailed individual accuracies are illustrated in Fig. 5B . Eleven accuracies exceeded 0.900. Similarly, when only the top 78 features were used, RIPPER yielded an MCC value of 0.762 and an overall accuracy of 0.772 ( Table 2) . This classifier was a good choice for making prediction because it was faster than the RIPPER with 249 features. Its performance on 33 cancer types is shown in Fig. 5B , which was only a little lower than that of the RIPPER with 249 features.
Compared with RF, RIPPER yielded reduced classification performance but produced numerous readable classification rules. As discussed above, for the feature list yielded by the mRMR method, RIPPER with top 48 features was an idea classifier; while for the list yielded by the MCFS method, RIPPER with top 78 features was a good choice. Therefore, the RIPPER was applied on these two sets of features to produce classification rules based on all 9664 cancer samples. 275 classification rules were produced on top 48 features yielded by mRMR method, which are listed in Table S7 . 302 classification rules learned by RIPPER on the basis of the top 78 features from MCFS, which are provided in Table S8 .
IV. DISCUSSION
In this study, we constructed two optimal classifiers with high classification accuracy of >0.940 to distinguish various tumor types. These classifiers were built on 126 and 211 selected features identified through the mRMR and MCFS method, respectively. In addition, top features analyzed by the mRMR and MCFS methods were then applied to generate 275 and 302 decision rules via RIPPER (Tables S7-S8 ). These rules could classify the cancer samples into corresponding categories with a high overall accuracy of >0.770. We focused on several top features and decision rules because they have a particular importance in classification, indicating that these features (e.g., the methylation level of these sites) likely play crucial roles in cancer processes. To validate the reliability of our findings, we examined existing experimental evidence through a wide literature review.
A. ANALYSIS OF THE TOP FEATURES IDENTIFIED BY THE MRMR METHOD
IFFO1 (probeID: cg08875705; cg22203219), a member of the intermediate filament family, is correlated with CA-125 levels in patient serum and can be an indicator of disease burden and relapse after tumor resection. The promoter methylation of IFFO1 is a candidate tumor marker given its frequent methylation detected in ovarian tumors [37] . Similarly, the expression and methylation level of IFFO1 are VOLUME 8, 2020 related to lung adenocarcinoma, indicating their strong potential as prognostic indicators for lung cancer [38] . These results suggest that IFFO1 has a significant effect in cancer process and exerts its effect through gene methylation at the DNA level.
FNDC3B (probeID: cg04319611), also named as fibronectin type III domain containing 3B, is a proteincoding gene that regulates cell motility. Recent publications have demonstrated that FNDC3B plays an important role in hepatocellular carcinoma by promoting cell migration and tumor metastasis [39] . Meanwhile, FNDC3B is a target of miR-143, the upregulated expression of which promotes the metastasis of prostate cancer cells by modulating FNDC3B expression [40] . Nuclear factor κB can adjust miR-143 to repress FNDC3B, and the downregulation of FNDC3B enhances invasion and migration capability [41] .
The protein encoded by INPP5A (probeID: cg26549601) is a membrane-associated type I inositol 1,4,5-trisphosphate 5-phosphatase. The overexpression of INPP5A inhibits cell proliferation and invasion capacity and promotes cell apoptosis [42] . A decrease in INPP5A expression levels seems to be a prior event in cutaneous squamous cell carcinoma, indicating that INPP5A may play an important role in tumor development and progression [43] .
The proto-oncogene SRC (probeID: cg24055525), which may play a role in the regulation of embryonic development and cell growth, is upregulated and highly activated in various types of human cancer, e.g., SRC, and affects the development of cell adhesion, invasion, proliferation, and survival [44] . The combined alteration of EGFR and SRC expression in fibroblasts improves the levels of tumorigenicity [45] . The high activation levels of phosphorylated SRC substrates in tumor cells indicate a strong link to metastasis and tumorigenicity induction [46] .
Protein produced by DCPS (probeID: cg15958289) protects cells with the capability of removing short mRNA fragments containing a cap structure; this process leads to potentially toxic-associated accumulation in the cell. The downregulation of DCPS expression could be a potential cause of the aberrant miRNA profiles observed in cancer [47] .
MAPK8IP3 (probeID: cg02330721), which is also known as JIP3, is a scaffold protein implicated in the JNK pathway [48] . This gene is overexpressed during the initiation and invasion period of pancreatic cancer, thus contributing to the further excessive proliferation of pancreatic cells [49] . The specific mutations of JIP3 influence the adhesion and invasion function of various cancer cells, suggesting the crucial role of JIP3 in cancer [50] .
The RNA-coding gene MIR141 (probeID: cg19794481) or microRNA-141 displays specific expression profiles and can be applied as a biomarker in various cancers. The increased expression of miR-141 is significantly associated with the survival and prognosis of patients with serous ovarian carcinoma [51] . The serum levels of miR-141 can be used to distinguish patients with prostate cancer from healthy individuals and represents a stable blood-based marker for prostate cancer diagnosis [52] . In addition, circulating plasma miR-141 is significantly correlated with stage IV colon cancer and could be applied as an independent prognostic factor for colon cancer [53] .
B. ANALYSIS OF THE TOP FEATURES IDENTIFIED BY THE MCFS METHOD
SLC22A23(probeID: cg26673629) belongs to a large family of transmembrane proteins that act as symporters and antiporters to transport organic ions across cell membranes [54] . A prediction model for the recurrence of triple negative breast cancer with high accuracy, sensitivity, and specificity was developed on the basis of several genes, including SLC22A23 [55] , and may provide evidence for the potential role of SLC22A23 in carcinogenesis. Meanwhile, the SLC22A23 gene was selected as a differentially expressed gene in a study aiming to identify crucial genes involved in the pathogenesis of laryngeal squamous cell carcinoma [56] . A similar conclusion was also confirmed in another research reporting that the expression of SLC22A23 is associated with laryngeal cancer [57] , suggesting that SLC22A23 may be involved in the development of laryngocarcinoma.
Zinc finger protein 500, abbreviated as ZNF500 (probeID: cg10278046; cg11422964), is a protein-coding gene that may VOLUME 8, 2020 participate in transcriptional regulation. This gene has been identified as a candidate gene for breast cancer risk given that the expression of ZNF500 exhibits consistent allelic expression imbalance with CCV genotype [58] . In fact, a growing body of evidence has revealed the potential roles of the zinc finger protein family in cancer progression. ZNF306 and ZNF309 promote cancer cell growth, migration, and angiogenesis in colorectal cancer [59] , [60] and can enhance cell proliferation in multiple myeloma [61] . ZNF388 and ZNF489 play crucial roles in lung cancer by modulating the target gene p53; this modulatory role leads to the migration and invasion of cancer cells [62] .
Five of the top 10 features identified by the MCFS method belong to the IFFO1 gene (cg17198308, cg00363813, cg08875705, cg23737737, and cg00983904), indicating that five methylation sites with particular classification importance are located in different regions of one gene. Notably, the two top-ranked features identified by mRMR method were also annotated in INFFO1. All these results strongly suggest that the methylation of IFFO1 gene has an important effect in cancer.
Genes in the ETS family are implicated in diverse cancers, such as sarcoma, acute myeloid leukemia, and chronic myelomoncytic leukemia [63] . The protein-coding gene ELF3 (probeID: cg26328757) has been identified as a member of the ETS gene family. The expression of ELF3 in lung carcinoma and adenovarcinoma is higher than in normal tissues [64] . Another study, which conducted experiments with overexpressed ELF3 in human breast ductal carcinoma in situ, confirmed that ELF3 can differentially activate several malignancy-associated gene promoters [65] . A recent work found that ELF3 is recurrently amplified and upregulated in colorectal cancer tissues. Moreover, ELF3 drives β-catenin transactivation and is significantly associated with the poor survival of colorectal cancer patients [66] .
The protein encoded by PPM1F (probeID: cg12894883) is a member of the PP2C family of Ser/Thr protein phosphatases. The overexpression of PPM1F rescues the miR149-mediated inhibition of cell migration and invasion in hepatocellular carcinoma, suggesting its facilitation effect and potential therapeutic target for HCC treatment [67] . 
C. ANALYSIS OF DECISION RULES IDENTIFIED ON THE BASIS OF THE MRMR METHOD
A total of 275 decision rules for distinguishing 33 different types of cancers were identified on the basis of the mRMR method. Among them, the top 10, which contains 81 criteria, could be used to identify pancreatic adenocarcinoma; the next five rules could be used to identify lymphoid neoplasm diffuse large B-cell lymphoma; the following six rules could identify kidney chromophobe; and cholangiocarcinoma could be identified by 10 rules. Using this approach, we could classify diverse cancer samples into their corresponding category on the basis of decision rules.
In the 16 rules identifying sarcoma, two criteria involved one feature (cg10518264) located in the HLA-DMB gene region and requiring high methylation. HLA-DMB belongs to HLA class II beta chain paralogues. A nested case-control study found that a mutation in HLA-DMB increases the risk of developing Kaposi's sarcoma [68] , suggesting the repression role of HLA-DMB in sarcoma. This finding is consistent with the rules predicted in our study that the aberrant expression of HLA-DMB caused by high methylation is an indicator of sarcoma.
The feature (cg01835695) involved in five rules identifying cervical squamous cell carcinoma was required to be in low methylation levels, showing that the hypomethylation of the annotated gene, MGAT1, is an indicator of cervical carcinoma. In vitro experiments have found that MGAT1, a member of the glycosyltransferase family, plays a crucial role in cancer progression [69] . The migration and invasion capability of HeLa cell was inhibited as demonstrated by MGAT1 knockdown experiment, indicating that MGAT1 likely promotes cervical carcinoma [70] . This conclusion confirmed our decision rules that low methylation levels of MGAT1 lead to a high risk of cervical carcinoma.
Among the 81 criteria involved in 10 rules that could be used to identify pancreatic adenocarcinoma, one feature (cg18440692) was required at low methylation levels in two criteria. This feature represents the methylation degree of one site located in FAM53B, a protein-coding gene that acts as a regulator of the Wnt signaling pathway. A research aiming to identify lncRNA biomarkers in pancreatic cancer showed that FAM53B antisense RNA1 (FAM53B-AS1) is positively associated with overall survival [71] . It implies that the upregulation of FAM53B may enhance the progression of pancreatic adenocarcinoma given that antisense RNA acts as an mRNA inhibitor and reduces protein expression. It is consistent with the decision rules that require the low methylation levels of FAM53B for identifying pancreatic cancer.
D. ANALYSIS OF DECISION RULES IDENTIFIED ON THE BASIS OF THE MCFS METHOD
We constructed 302 rules from 78 features involved in 1,572 criteria on the basis of the MCFS method. Among the 17 decision rules that could indicate bladder urothelial carcinoma, four rules attracted our attention. Two features (cg25042226 and cg06881093) are both required in low methylation levels in the decision rules. These features are located in the region of PAX8, which encodes a member of the paired box family of transcription factors. Immunohistochemical and RT-PCR studies have shown that PAX8 is expressed in the majority of bladder urothelial neoplasis but not in normal adult urothelial epithelium [72] . Moreover, the expression of PAX8 may contribute to urothelial tumorigenesis through p53 given that PAX8 inhibits p53 expression [73] , and the absence of p53 promotes urothelial cell proliferation [74] . The rules that required hypomethylation lead to the high expression of PAX8, which may enhance the development of bladder urothelia carcinoma.
A criterion that required the hypermethylation of CUX1 (cg06010390) to identify pancreatic adenocarcinoma is found to have experimental support. The transcription factor CUX1 is a regulator of cell differentiation and cell cycle progression. The accumulated evidence revealed that reduced CUX1 expression facilitates tumor initiation. The partial knockdown of CUX1 in human cord blood progenitors caused an increase in engraftment upon transplantation into immunodeficient mice [75] . Increased tumor formation was found with CUX1 knockdown in T-cell acute lymphoblastic leukemia cells after subcutaneous injection into immunodeficient mice [76] . These results have established that CUX1 acts as a tumor suppresser gene and that the reduced expression of CUX1 can promote tumor cell proliferation.
In the 17 rules identifying lung squamous cell carcinoma, three criteria require that the important gene DPP9 (cg01098142) remain at low mehtylation levels. DPP9 encodes a protein that is a member of the ubiquitous atypical serine proteases family, which has been linked to various diseases, including type 2 diabetes, obesity, and cancer [77] . A recent study reported that the expression levels of DPP9 are significantly increased in non-small cell lung cancer (NSCLC) tissues compared with adjacent normal tissues and are highly correlated with a poor overall survival rate in patients with NSCLC [78] . Furthermore, loss-offunction experiments demonstrated that the downregulation of DPP9 suppresses the proliferation, migration, and invasion of NSCLC cells, suggesting the potential tumor promotion role of DPP9 in NSCLC. These results confirmed our decision rules that the upregulation of DPP9 by demethylation could contribute to the progression of lung carcinoma.
We applied the mRMR and MCFS methods together to identify diverse decision rules from the PanCanAtlas data with the aim to distinguish different tumor types on the methylation level. Our decision rules can distinguish 33 different tumor types. The ranked features can be used to characterize the methylation levels of different cancer sites and provide insight into the novel therapeutic targets. This study highlights the wide application potential of methylation features in cancer diagnosis.
V. CONCLUSION
In this study, the methylation profiles on samples in 33 cancer types were deeply analyzed by some machine learning algorithms. Some important methylation features and classification rules were accessed. Genes related to important methylation features and rules were extensively discussed. Hopefully, the new findings reported in this study may give new insights on pan-cancer study based on methylation.
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